Elevated Levels of Interleukin-18 are Associated with Lymph Node
                    Metastasis in Papillary Thyroid Carcinoma

Wang Chun; Meiyin Lu; Jiakang Chen; Jian Li

doi:10.1055/a-2255-5718

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2024; 56(09): 654-661
DOI: 10.1055/a-2255-5718

Original Article: Endocrine Care

Elevated Levels of Interleukin-18 are Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Autor*innen

Wang Chun

¹Pathology, Peking University Shenzhen Hospital, Shenzhen, China
Meiyin Lu

²Graduate School, Shantou University Medical College, Shantou, China

³Department of Biobank, Shenzhen Baoan Womenʼs and Children's Hospital, Shenzhen, China
Jiakang Chen

¹Pathology, Peking University Shenzhen Hospital, Shenzhen, China
Jian Li

¹Pathology, Peking University Shenzhen Hospital, Shenzhen, China

⁴State Key Laboratory of Chemical Oncogenomics, Peking University Shenzhen Graduate School, Shenzhen, China

Abstract

Interleukin-18 (IL-18) is a proinflammatory cytokine that primarily stimulates the Th1 immune response. IL-18 exhibits anticancer activity and has been evaluated in clinical trials as a potential cancer treatment. However, evidence suggests that it may also facilitate the development and progression of some cancers. So far, the impact of IL-18 on papillary thyroid cancer (PTC) has not been investigated. In this study, we found that the expression of IL-18 was significantly increased in PTC compared to normal thyroid tissue. Elevated IL-18 expression was closely associated with lymphovascular invasion and lymph node metastases. Furthermore, compared to PTC patients with no nodal metastasis, serum IL-18 levels were slightly increased in patients with 1–4 nodal metastases and significantly elevated in patients with 5 or more nodal metastases. The pro-metastatic effect of IL-18 may be attributed to the simultaneous increase in the expression of S100A10, a known factor that is linked to nodal metastasis in PTC. In addition, the activation of several pathways, such as the intestinal immune network for lgA production and Staphylococcus aureus infection, may be involved in the metastasis process. Taken together, IL-18 may trigger pro-metastatic activity in PTC. Therefore, suppressing the function of IL-18 rather than enhancing it appears to be a reasonable strategy for treating aggressive PTC.

Keywords

IL-18 - papillary thyroid carcinoma - serum - lymph node metastasis - S100A10

Volltext

Referenzen

References
1 Xu M, Xi Z, Zhao Q. et al. Causal inference between aggressive extrathyroidal extension and survival in papillary thyroid cancer: a propensity score matching and weighting analysis. Front Endocrinol (Lausanne) 2023; 14: 1149826
2 Tan LC, Huang NS, Yu PC. et al. Different clinicopathologic features predispose to different patterns of distant metastasis with heterogeneous short-term prognosis in patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2022; 96: 402-412
3 Esmailbeig M, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. Eur Cytokine Netw 2017; 28: 127-140
4 Ihim SA, Abubakar SD, Zian Z. et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front Immunol 2022; 13: 919973
5 Shimizu M, Takei S, Mori M. et al. Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases. Front Immunol 2022; 13: 951535
6 Fang Y, Tian S, Pan Y. et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother 2020; 121: 109595
7 Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol 2015; 97: 665-675
8 Iwasaki T, Yamashita K, Tsujimura T. et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother 2002; 25: S52-S60
9 Nishio S, Yamada N, Ohyama H. et al. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci 2008; 99: 113-120
10 Xu G, Jiang XD, Xu Y. et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 2009; 33: 466-474
11 Srivastava S, Pelloso D, Feng H. et al. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother 2013; 62: 1073-1082
12 Ye ZB, Ma T, Li H. et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007; 13: 1747-1751
13 Ma T, Kong M. Interleukin-18 and -10 may be associated with lymph node metastasis in breast cancer. Oncol Lett 2021; 21: 253
14 Xu L, Zhu Y, An H. et al. Clinical significance of tumor-derived IL-1beta and IL-18 in localized renal cell carcinoma: associations with recurrence and survival. Urol Oncol 2015; 33: 68 e69-e16
15 Wang X, Zhu YF, Li DM. et al. Polymorphisms of ST2-IL18R1-IL18RAP gene cluster: a new risk for autoimmune thyroid diseases. Int J Immunogenet 2016; 43: 18-24
16 Jamshidi M, Farnoosh G, Mohammadi Pour S. et al. Genetic variants and risk of thyroid cancer among Iranian patients. Horm Mol Biol Clin Investig 2021; 42: 223-234
17 Lazow MA, Fuller C, Trout AT. et al. Immunohistochemical assessment and clinical, histopathologic, and molecular correlates of membranous somatostatin type-2A receptor expression in high-risk pediatric central nervous system tumors. Front Oncol 2022; 12: 996489
18 Masugi Y, Yamazaki K, Emoto K. et al. Upregulation of integrin beta4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Lab Invest 2015; 95: 308-319
19 Zhang Z, Zhao S, Wang K. et al. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: evidence from an integrated bioinformatic analysis. Clin Hemorheol Microcirc 2021; 78: 117-126
20 Nipp M, Elsner M, Balluff B. et al. S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med (Berl) 2012; 90: 163-174
21 Palma G, Barbieri A, Bimonte S. et al. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 2013; 1836: 296-303
22 Park H, Byun D, Kim TS. et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001; 79: 215-219
23 Terme M, Ullrich E, Aymeric L. et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-5399
24 Kim J, Kim C, Kim TS. et al. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 2006; 344: 1284-1289
25 Kang JS, Bae SY, Kim HR. et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis 2009; 30: 1987-1996
26 Jiang DF, Liu WL, Lu YL. et al. Function of IL-18 in promoting metastasis of lung cancer. Zhonghua Zhong Liu Za Zhi 2003; 25: 348-352
27 Gunel N, Coskun U, Sancak B. et al. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003; 26: 416-421
28 Li B, Wang F, Ma C. et al. Predictive value of IL-18 and IL-10 in the prognosis of patients with colorectal cancer. Oncol Lett 2019; 18: 713-719
29 Diakowska D, Markocka-Maczka K, Grabowski K. et al. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol 2006; 28: 319-322
30 Okamoto M, Azuma K, Hoshino T. et al. Correlation of decreased survival and IL-18 in bone metastasis. Intern Med 2009; 48: 763-773
31 Ma R, Yu Y, Liu X. et al. Transcriptomic analysis of Nibea albiflora skin in response to infection by cryptocaryon irritans. Fish Shellfish Immunol 2020; 98: 819-831
32 Wang S, Li M, Jiang Y. et al. Transcriptome analysis reveals immune regulation in the spleen of koi carp (Cyprinus carpio Koi) during aeromonas hydrophila infection. Mol Immunol 2023; 162: 11-20
33 Zhan S, Wang T, Wang M. et al. In-depth proteomics analysis to identify biomarkers of papillary thyroid cancer patients older than 45 years with different degrees of lymph node metastases. Proteomics Clin Appl 2019; 13: e1900030
34 Bharadwaj A, Kempster E, Waisman DM. The annexin A2/S100A10 complex: the mutualistic symbiosis of two distinct proteins. Biomolecules 2021; 11: 1849
35 Kwon M, MacLeod TJ, Zhang Y. et al. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005; 10: 300-325
36 Sowder AM, Witt BL, Hunt JP. An update on the risk of lymph node metastasis for the follicular variant of papillary thyroid carcinoma with the new diagnostic paradigm. Head Neck Pathol 2018; 12: 105-109
37 Raffaelli M, De Crea C, Sessa L. et al. Risk factors for central neck lymph node metastases in follicular variant vs. classic papillary thyroid carcinoma. Endocrine 2018; 62: 64-70
38 Simpkins F, Flores A, Chu C. et al. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. . Cancer Immunol Res 2013; 1: 168-178
39 Robertson MJ, Kline J, Struemper H. et al. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother 2013; 36: 331-341
40 Carbone A, Vizio B, Novarino A. et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother 2009; 32: 920-931
41 Lu G, Chen L. Cervical lymph node metastases in papillary thyroid cancer: Preoperative staging with ultrasound and/or computed tomography. Medicine (Baltimore) 2022; 101: e28909
42 Wang R, Tang Z, Wu Z. et al. Construction and validation of nomograms to reduce completion thyroidectomy by predicting lymph node metastasis in low-risk papillary thyroid carcinoma. Eur J Surg Oncol 2023; 49: 1395-1404

Zusatzmaterial

Supplementary Material (PDF) (opens in new window)